Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YU1L
|
|||
| Former ID |
DNCL001792
|
|||
| Drug Name |
MP-124
|
|||
| Indication | Ischemic stroke [ICD-11: 8B11.5Z; ICD-9: 434.91] | Phase 1 | [1] | |
| Stroke [ICD-11: 8B20; ICD-10: I64] | Phase 1 | [2] | ||
| Company |
Mitsubishi Tanabe Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Poly [ADP-ribose] polymerase (PARP) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model. Brain Res. 2011 Sep 2;1410:122-31. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Company report (Mitsubishi Tanabe Pharma) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.